Back to news

Polaryx Therapeutics Highlights Participation in NCL Scientific Conference and NTSAD Imagine & Believe Event

Globe Newswire•20/11/2026•08:30 ET
0

Key Highlights

  • ➤First SOTERIA site activated at Boys Town National Research Hospital in Nebraska
  • ➤SOTERIA Phase 2 will evaluate PLX-200 across four rare pediatric LSDs
  • ➤SOTERIA planned to initiate in fourth quarter of 2026 across U.S., Europe and Asia
  • ➤PLX-200 could pursue expedited approval if data demonstrate compelling clinical activity

Expert Statements

Alex Yang, Chair and Chief Executive Officer of Polaryx Therapeutics

“Advancing therapies for rare pediatric diseases requires close engagement with the scientific community and the families whose lives are affected by these conditions.”

Alex Yang, Chair and Chief Executive Officer of Polaryx Therapeutics

“Following activation of our first SOTERIA clinical trial site, these events provided an important opportunity to share our development progress and reinforce our commitment to the patient communities we aim to serve.”

Alex Yang, Chair and Chief Executive Officer of Polaryx Therapeutics

“We remain focused on translating our research into carefully conducted clinical studies that can help address the significant unmet needs of children and families living with these devastating diseases.”

PARAMUS, NJ, Nov. 20, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX) ("Polaryx" or the "Company"), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare pediatric lysosomal storage disorders (LSDs), today highlighted its participation in the 9th NCL Translational Science and Therapeutics Conference and the National Tay-Sachs & Allied Diseases Association’s (NTSAD) Imagine & Believe event in the Boston area. The Company’s participation reflects its commitment to engaging with researchers, clinicians, patient advocates and families as it advances development of its lead investigational drug candidate, PLX-200, across four rare pediatric LSDs.

At the NCL conference, held November 11–13, 2026, at the Marriott Boston Quincy in Quincy, Massachusetts, Will Charlton, M.D., M.A.S., Polaryx Therapeutics’ Chief Medical Officer, presented an update on the Company’s development program, including previously published preclinical findings in a CLN3 mouse model. His presentation took place on Friday, November 13, as part of the session titled, “Clinical Program Updates II: Small Molecules, ERTs and Other Therapeutic Approaches.”

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in